StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3
RCRP052
Brand: StemEdit
Human StemRNA Clinical iPSCs with a knockout of both copies of the B2M and CIITA genes.
| Product name | Catalog number | Pack size | Price | Price | Price (USD) | Price (GBP) | Price (EUR) |
|---|---|---|---|---|---|---|---|
| StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3 | RCRP052 | 1 × 10⁶ cells | Ask us | $ 10000.00 | £ Ask us | € Ask us |
Note: prices shown do not include shipping and handling charges.
Product Information
Recommended Products
- iMatrix-511 Stem Cell Culture Substrate NP892-011 / NP892-012
- NutriFreez™ D10 Cryopreservation Medium 01-0020-50
- NutriStem™ hPSC XF Culture Medium for Human iPS and ES Cells 01-0005 / 01-0005-100
Ready-to-use Research-Grade HLA Class I and II double knockout iPSCs made using REPROCELL’s RNA Reprogramming Technology.
These cells feature all the advantages of our RNA reprogramming technology, including no retention of reprogramming factors and easy culture in NutriStem hPSC XF Medium (Cat. No. 01-0005). They have been engineered using OpenCRISPR-1 to contain B2M (HLA Class I) and CIITA (HLA Class II) double knockout mutation, which is carefully characterized and offers significant time savings compared to creating your own reprogrammed and edited cell lines.
NOTE:
These iPSC cell lines are developed and supplied for Research Use Only (RUO). They are not intended for clinical or therapeutic applications. However, this clone has a clinical-grade counterpart available that is suitable for clinical gene editing and downstream clinical development. If you require material for translational or clinical programs, please see Clinical Stem Cell Services or Contact Us for more information.
See also our complete collection of Research Use Only StemRNA™ Induced Pluripotent Stem Cells (iPSCs).
Table: Characteristics of StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3 Cells
| Cat. No.: | RCRP052 |
| Mutation: | B2M/CIITA double knockout |
| Mutation validation: |
DNA Sequencing, B2M expression (flow) |
| Parent Strain ID: |
StemRNA Clinical iPSC Clone LLF-34-F3 |
| Donor Blood Type: |
O positive |
| Donor Race: | Caucasian |
| Donor Sex: | Female |
| Donor Age: | 22 |
| Reprogramming Technology: | StemRNA Clinical Reprogramming Technology |
| Tissue Source: | Skin (Fibroblasts) |
| Karyotype: | Normal (46 XX) |
| Microbiology: | Negative for bacteria, virus, and mycoplasma |
Figure: Immunofluorescence staining (Figure) and flow cytometry analysis (Table) for Pluripotency Markers
|
Marker |
Flow Positive Cells |
|
OCT4 |
94.5% |
|
Nanog |
98.9% |
|
SSEA4 |
97.9% |
|
SSEA1 (neg control) |
0% |
Figure: Expression of B2M in Double Knockout and unedited Wild Type iPSCs 
The Role of B2M and CIITA
In humans, the B2M protein is required for the presentation of HLA proteins A-G on the cell surface. Disruption of the B2M gene reduces T-cell activation and interferes with the T-cell-mediated immune response through inhibition of Class I HLA signaling. CIITA regulates the expression of the HLA Class II complex. Knocking out CIITA leads to reduced activity of HLA Class II and suppression of the immune response.
Explore our other StemEdit Research iPSCs.
Stemgent and the StemEdit brand name are trademarks of REPROCELL Inc., Japan.